Patent intelligence · US
US 9017725
Topical drug delivery systems for ophthalmic use
Topical drug delivery systems for ophthalmic use
Patent details — US 9017725
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 28, 2015
- Expiration
- Apr 23, 2035
- Applicant
- AURINIA PHARMACEUTICALS INC.
- Claims
- 16
- CPC classes
- A61K, A61K31/14, A61K31/436, A61K31/573
Quick answer
US 9017725 (Topical drug delivery systems for ophthalmic use) is held by AURINIA PHARMACEUTICALS INC.. Status: granted. Granted Apr 28, 2015. Expires Apr 23, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- AURINIA PHARMACEUTICALS INC.
- Grant date
- Expiration
- Claims
- 16
- CPC classes
- A61K, A61K31/14, A61K31/436, A61K31/573, A61K47/10, A61K47/22
More from AURINIA PHARMACEUTICALS INC.
Related pharmaceutical patents in our USPTO index.
-
US 11622991
Protocol for treatment of lupus nephritis
granted -
US 10973871
Ophthalmic compositions
granted -
US 10472394
Cyclosporine analogue mixtures and their use as immunomodulating agents
granted -
US 10286036
Protocol for treatment of lupus nephritis
granted -
US 10265375
Ophthalmic compositions
granted -
US 9765119
Cyclosporine analogue mixtures and their use as immunomodulating agents
granted
Frequently asked questions
What is US patent 9017725?
US 9017725 (Topical drug delivery systems for ophthalmic use) is held by AURINIA PHARMACEUTICALS INC.. Status: granted. Granted Apr 28, 2015. Expires Apr 23, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9017725?
AURINIA PHARMACEUTICALS INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 7 pharmaceutical patents for this assignee.
When does US 9017725 expire?
Our index shows an expiration date of Apr 23, 2035 (9 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.